A Phase 2 interventional study of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL in Chronic Limb Ischemia, sponsored by Mercator MedSystems, Inc.. Status unknown at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-19.
Sponsored by Mercator MedSystems, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Ischemia with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Ischemia · United States.
Among the 155 studies in Ischemia with a site in United States, this one is the 35th largest by planned enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2016, is one of 24 in phase 2, and was the 104th registered.
545 studies on the registry are indexed under Ischemia; 71 are open to participants now.
Browse Ischemia studies →20 of the 155 studies in Ischemia with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 40+
Baylor Research Institute · Sites in United States
Ages 18+
Penumbra Inc. · Sites in United States, Australia, Brazil and 4 more countries
Ages 18+
Samaritan Biologics · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 36 · Phase 3 13 · Phase 4 7
First in 1993; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 74 across 356 interventional studies indexed under Ischemia.
Median enrollment 60 across the 100 interventional studies, 191 across the 53 observational. Of the 109 that completed or were terminated, 38 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 155 have an industry lead sponsor. The 10 most frequent:
Mercator MedSystems, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Mercator MedSystems, Inc. has 3 studies filed under Ischemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Ischemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06271577AliveCorSmartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II | 2026-12 |
| NCT06437028Samaritan BiologicsEvaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers. | 2027-03 |
| NCT00762333UConn HealthCirculating Markers for Ischemic Heart Disease | 2027-03 |
| NCT06896903Baylor Research InstituteAnalysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 155 studies in Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).
This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI). Up to 120 patients (60 treatment and 60 control), including up to 20 Rutherford 6 patients (10 treatment and 10 control) at up to 30 sites in the United States and Europe. This study will assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial deposition of dexamethasone in reducing inflammation and restenosis in patients with clinical evidence of chronic critical limb ischemia with an angiographically significant lesion in the infrapopliteal crural vessels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Screening Criteria:
Angiographic Criteria:
Exclusion Criteria:
Screening Criteria:
Angiographic/Procedural Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe. For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution.
Drug: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL
Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe. Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control.
Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
Freedom from MALE
Freedom from major adverse limb event (MALE) within 6 months.
Time frame: Up to 6 Months following the procedure
Freedom from CD-TLR
Freedom from clinically driven target lesion revascularization (CD-TLR) within 6 months.
Time frame: Up to 6 Months following the procedure
Composite clinical safety by freedom from adverse events including death, MALE, major unplanned amputation, or CD-TLR.
Freedom from composite of death within 30 days from the index procedure, MALE, major unplanned amputation or CD-TLR within 6 months.
Time frame: Up to 6 Months following the procedure
TVAL% change from post-procedure
Transverse-view vessel area loss percentage (TVAL%) of the target lesion at 6 months by quantitative vascular angiography (QVA) or prior to any CD-TLR of the target lesion before 6 months
Time frame: 6 Months following the procedure
Composite clinical safety by freedom from adverse events including death, unplanned amputation, CD-TLR, SAE or MALE.
Freedom from composite of death, unplanned amputation and CD-TLR, serious adverse events (SAE) and MALE.
Time frame: Up to 12 months following the procedure
Event-free survival
Proportion of patients reaching 12-month endpoint without a composite clinical safety event.
Time frame: 12 months following the procedure
QVA change from post-procedure
Improvement in % diameter stenosis (%DSS) of the target lesion (TL) and the maximum late lumen loss for the lesion (LLL) will be assessed by quantitative vascular angiography (QVA).
Time frame: 6 months following the procedure
IVUS change from post-procedure
Improvement in intravascular ultrasound (IVUS) result with in the TL (subgroup analysis).
Time frame: 6 months following the procedure
Amputation-free survival
Percentage of patients reaching the endpoints without major or minor amputation.
Time frame: 30 days, 6 and 12 months following the procedure
Major and minor amputations and amputation level
Percentage of patients requiring amputation (major: above ankle, minor: below ankle), categorized by level on the foot, ankle, or leg.
Time frame: 30 days, 6 and 12 months following the procedure
Change in foot wounds versus baseline
The number and total size of foot wounds, reduction in number and size of baseline wounds, and occurrence of new wounds (number and size) will be measured against baseline.
Time frame: 30 days, 6 and 12 Months following the procedure
Resolved CLI death
The rate of deaths in patients who had a resolution of their critical limb ischemia (CLI).
Time frame: 30 days, 6 and 12 months following the procedure
CD-TLR
Time frame: 30 days, 6 and 12 months following the procedure
Primary sustained clinical improvement versus baseline
Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
Time frame: 30 days, 6 and 12 months following the procedure
Secondary sustained clinical improvement versus baseline
Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
Time frame: 30 days, 6 and 12 months following the procedure
SVS WIfI score versus baseline
Time frame: 30 days, 6 and 12 months following the procedure
EQ5D versus baseline
Time frame: 30 days, 6 and 12 months following the procedure
Walking capacity assessment versus baseline
Time frame: 30 days, 6 and 12 months following the procedure
SAE/MALE assessment
Time frame: 30 days, 6 and 12 months following the procedure
Inflammatory biomarker changes from baseline
Time frame: 24 hours and 30 days
Healthcare economic analysis
An analysis of the economics associated with the care of patients, including number of hospital days throughout the study, return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions.
Time frame: From baseline to 24 months
Infustion technical success
The grade of distribution (A-F) around infusion sites will be used as a qualitative measure of technical success of adventitial delivery of the drug.
Time frame: Intra-procedural
Revascularization success
Establishment of antegrade flow with residual stenosis \<30% by angiogram.
Time frame: Intra-procedural
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Jun 2016 to primary completion in Nov 2019, 41 months.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mercator MedSystems, Inc.